Remission of Hepatitis B Virus-Related Vasculitis with Lamivudine
Authors: Takuya Sawabe, Takeshi Uenotsuchi, Shinichi Imafuku, Hiroshi Kohno, Junichi Arima, Takahiko Horiuchi
Journal: Annals of Internal Medicine (2004)

Letters20 April 2004Remission of Hepatitis B Virus-Related Vasculitis with LamivudineTakuya Sawabe, MD, PhD, Takeshi Uenotsuchi, MD, Shinichi Imafuku, MD, Hiroshi Kohno, MD, Junichi Arima, MD, PhD, and Takahiko Horiuchi, MD, PhDTakuya Sawabe, MD, PhDFrom Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima 730-8619, and Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.Search for more papers by this author, Takeshi Uenotsuchi, MDFrom Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima 730-8619, and Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.Search for more papers by this author, Shinichi Imafuku, MDFrom Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima 730-8619, and Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.Search for more papers by this author, Hiroshi Kohno, MDFrom Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima 730-8619, and Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.Search for more papers by this author, Junichi Arima, MD, PhDFrom Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima 730-8619, and Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.Search for more papers by this author, and Takahiko Horiuchi, MD, PhDFrom Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima 730-8619, and Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-8-200404200-00035 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: Lamivudine is a nucleoside analogue approved for treating chronic hepatitis B (1, 2), and one case report has suggested that it may also be effective for treating vasculitis associated with hepatitis B virus (HBV) infection (3). We describe a patient whose cryoglobulinemic vasculitis associated with HBV infection was ameliorated after additional administration of lamivudine.Case Report: A 48-year-old woman was admitted to our hospital with skin ulcers on 9 September 2000. She had had polyneuropathy in 1985. On admission, she had multiple skin ulcers on her feet, fever, and decreased sensation in the distal extremities. Urinalysis ...References1. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al . A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-8. [PMID: 9654535] CrossrefMedlineGoogle Scholar2. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al . Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-63. [PMID: 10528035] CrossrefMedlineGoogle Scholar3. Gupta S, Piraka C, Jaffe M. Lamivudine in the treatment of polyarteritis nodosa associated with acute hepatitis B [Letter]. N Engl J Med. 2001;344:1645-6. [PMID: 11374371] CrossrefMedlineGoogle Scholar4. Cacoub P, Costedoat-Chalumeau N, Lidove O, Alric L. Cryoglobulinemia vasculitis. Curr Opin Rheumatol. 2002;14:29-35. [PMID: 11790993] CrossrefMedlineGoogle Scholar5. Della Rossa A, Tavoni A, Baldini C, Bombardieri S. Treatment of chronic hepatitis C infection with cryoglobulinemia. Curr Opin Rheumatol. 2002;14:231-7. [PMID: 11981318] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima 730-8619, and Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEntecavir to Treat Hepatitis B–Associated Cryoglobulinemic Vasculitis Masaru Enomoto , Takeshi Nakanishi , Masamitsu Ishii , Akihiro Tamori , and Norifumi Kawada Metrics Cited ByHepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie – GISCManagement of Vasculitic GlomerulonephritisNon HCV-related infectious cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey and systematic review of the literatureTelbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapyComparison of cryoglobulinemia in children and adultsSuccessful Lamivudine Monotherapy in an Elderly Patient Suffering from HBV-Related Decompensated Cirrhosis Associated with Widespread Leukocytoclastic VasculitisEntecavir to Treat Hepatitis B–Associated Cryoglobulinemic VasculitisMasaru Enomoto, MD, Takeshi Nakanishi, MD, Masamitsu Ishii, MD, Akihiro Tamori, MD, and Norifumi Kawada, MDSuccessful treatment of hepatitis B-associated leukocytoclastic vasculitis with lamivudine treatment in a child patientManagement of chronic hepatitis B virus infection: a new era of disease controlSuccessful Treatment with Adefovir of One Patient Whose Cryoglobulinemic Vasculitis Relapsed under Lamivudine Therapy and Who was Diagnosed to Have HBV Virologic Breakthrough with YMDD Mutations 20 April 2004Volume 140, Issue 8Page: 672-673KeywordsAminotransferasesAntigensChronic hepatitis BDNAHepatitis BHepatitis C virusImmune complexInfectious hepatitisUlcersVasculitis ePublished: 20 April 2004 Issue Published: 20 April 2004 CopyrightCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...